FDA panel to consider case for Arcoxia

An expert FDA panel is scheduled to meet on Thursday to review the highly controversial case for Merck's Arcoxia, a would-be successor to Vioxx. Just days ago, two top researchers in the field warned against any approval for Arcoxia, saying that the risks far exceeded the potential rewards. Merck, for its part, is betting that the $500 million already invested in Arcoxia can still earn some kind of payback if the FDA will approve the cox-2 inhibitor for a segment of the market. And they're hoping that the different molecular structure involved in Arcoxia will help scientists distinguish its potential risks from the debacle that surrounded Vioxx. This will be a very closely watched vote.

- read this Philadelphia Inquirer report on the debate over Arcoxia

ALSO: Steve Nissen from the Cleveland Clinic had some tough criticism for Arcoxia. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.